Evaluating Ebola therapies - The case for RCTs

New England Journal of Medicine

Volumn 371, Issue 25, 2014, Pages 2350-2351

  Cox, Edward ^a   Borio, Luciana ^a   Temple, Robert ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG EFFICACY; DRUG SAFETY; EBOLA HEMORRHAGIC FEVER; HEALTH CARE DISTRIBUTION; HUMAN; MORTALITY; NONHUMAN; PATIENT CARE; PUBLIC HEALTH; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESOURCE ALLOCATION; REVIEW; RISK BENEFIT ANALYSIS; STUDY DESIGN; SURVIVAL RATE; EBOLA VIRUS; EPIDEMIC; HEMORRHAGIC FEVER, EBOLA;

EBOLAVIRUS; EPIDEMICS; HEMORRHAGIC FEVER, EBOLA; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84919344029     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMp1414145     Document Type: Article

References (5)

1. WHO Ebola Response Team. Ebola virus disease in West Africa - the first 9 months of the epidemic and forward projections. N Engl J Med 2014;371:1481-95.
2. Joffe S. Evaluating novel therapies during the Ebola epidemic. JAMA 2014;312:1299-300.
3. Adebamowo C, Bah-Sow O, Binka F, et al. Randomised controlled trials for Ebola: practical and ethical issues. Lancet 2014;384: 1423-4.
4. Ebola virus disease: fact sheet no. 103, updated September 2014. Geneva: World Health Organization (http://www.who.int/mediacentre/factsheets/fs103/en).
5. Lamontagne F, Clément C, Fletcher T, Jacob ST, Fischer WA II, Fowler RA. Doing today's work superbly well - treating Ebola with current tools. N Engl J Med 2014;371: 1565-6.